Studies were carried out to assess the ability of thymosin α1 to prolong the survival of mice challenged with Candida albicans. Two- to four-month-old mice were treated with graded doses of thymosin α1 before, after, or before and after intravenous challenge with C. albicans. Significant resistance to lethal infection was afforded by 100 μg of thymosin α1 per kg given before or before and after challenge, whereas no protection was found in mice treated with thymosin α1 administered at any dose level after inoculation. Pretreatment with thymosin α1 also prevented the increased susceptibility to C. albicans infection of mice pretreated with cyclophosphamide on day -6. The results showed that thymosin α1 was capable of protecting untreated or cyclophosphamide-pretreated mice from C. albicans infection at an optimal dose and schedule of administration.
|Number of pages||6|
|Journal||Infection and Immunity|
|Publication status||Published - 1982|
ASJC Scopus subject areas